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The use of human mesenchymal stem cells (hMSCs) has emerged as a possible therapeutic strategy forAU4c CNS-
related conditions. Research in the last decade strongly suggests that MSC-mediated benefits are closely related
with their secretome. Studies published in recent years have shown that the secretome of hMSCs isolated from
different tissue sources may present significant variation. With this in mind, the present work performed a
comparative proteomic-based analysis through mass spectrometry on the secretome of hMSCs derived from
bone marrow (BMSCs), adipose tissue (ASCs), and human umbilical cord perivascular cells (HUCPVCs). The
results revealed that BMSCs, ASCs, and HUCPVCs differed in their secretion of neurotrophic, neurogenic,
axon guidance, axon growth, and neurodifferentiative proteins, as well as proteins with neuroprotective actions
against oxidative stress, apoptosis, and excitotoxicity, which have been shown to be involved in several CNS
disorder/injury processes. Although important changes were observed within the secretome of the cell popu-
lations that were analyzed, all cell populations shared the capability of secreting important neuroregulatory
molecules. The difference in their secretion pattern may indicate that their secretome is specific to a condition
of the CNS. Nevertheless, the confirmation that the secretome of MSCs isolated from different tissue sources is
rich in neuroregulatory molecules represents an important asset not only for the development of future neu-
roregenerative strategies but also for their use as a therapeutic option for human clinical trials.
Introduction
Over the last two decades, human mesenchymalAU5c stemcells (hMSCs) have been widely studied due to their
potential applications in regenerative medicine [1]. In addi-
tion to their capacity for self-renewal and multilineage dif-
ferentiation potential, it is recognized that the secretome of
hMSCs plays a crucial role in the mediation of several cell
processes that contribute toAU4c CNS protection and/or regener-
ation in different pathological conditions [1]. Indeed, pre-
clinical in vitro [2–5] and in vivo [6] studies have shown that
the molecules secreted by different hMSC populations,
namely bone marrow (BMSCs), adipose tissue (ASCs), and
human umbilical cord perivascular cells (HUCPVCs), are
able to (1) promote neuronal survival and neurite outgrowth,
(2) increase levels of neurogenesis and angiogenesis; (3) in-
hibit apoptosis and scarring, (4) modulate immune response,
and (5) improve functional outcomes in different models of
CNS injury and disease, such as brain ischemia, spinal cord
injury (SCI), Parkinson’s disease (PD), and Alzheimer’s
disease (AD). In addition, these studies also revealed that
these hMSC secretome-mediated cell processes contribute to
the improvement of animals’ functional recovery following
hMSC transplantation. Nevertheless, although these different
hMSC populations share similar phenotypical characteristics
[7,8] and exhibit proregenerative potential, they reside in
different anatomic parts of the body and, therefore, it is most
likely that they present differences in their secretome. In fact,
Ribeiro et al. [9] conducted a screening on the presence of
some neuronal survival and differentiation growth factors in
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ASC and HUCPVC secretomes, revealing important differ-
ences in the secretome composition between these two pop-
ulations. While ASC CM was positive for the presence of
hepatocyte growth factor (HGF), vascular endothelial growth
factor (VEGF), stem cell factor, and nerve growth factor
(NGF), only NGF andVEGFwere detected in HUCPVCCM.
On the other hand, Nakanishi et al. [8] demonstrated that there
were significant differences in the growth factors and cyto-
kines secreted by rat-derived ASCs and BMSCs. While
ASCs secreted higher amounts of angiogenic and anti-
apoptotic growth factors, such as HGF and VEGF, as well as
interleukin-6 (IL-6), BMSCs secreted cell migration-related
chemokine stromal cell-derived factor 1 alpha (SDF-1a) [8].
Hsieh et al. [10] also revealed that although both superna-
tants collected from MSCs derived from Wharton’s jelly
(WJMSCs) and BMSCs contained angiogenesis-related fac-
tors, the secreted factors were distinct. Nevertheless, although
all of the above-referenced studies have established that there
are important differences among the secretomes of different
hMSC populations, the fact remains that only targeted pro-
teomic approaches have been used for this purpose. Being so,
these studies provide only a narrow window of the soluble
factors secreted by MSCs. Given the vast panel of functional
roles attributed to hMSCs in the mediation of paracrine ac-
tions that ultimately contribute for CNS repair, an unbiased,
global proteomics approach would better clarify the potential
complexity of hMSC secretome. In this sense, a shotgun/
discovery proteomics-based approach, in which liquid chro-
matography (LC) is used to identify and quantify proteins
present in hMSC secretome, offers a more broader analysis of
hMSC-secreted proteins. Fraga et al. [11], using LC coupled
with tandem mass spectrometry (LC-MS/MS), were able to
identify and quantify the expression of several proteins in the
HUCPVC secretome that were, to date, not known to be se-
creted by these cells. Importantly, in this study, the au-
thors identified proteins, such as 14-3-3, ubiquitin-carboxy-
terminal hydrolase 1 (UCHL1), heat shock protein 70, and
peroxiredoxin-6, which are involved in the regulation of neu-
ronal cell survival/protection, proliferation, and differentiation.
Having this in mind, in the present work, we aimed to (1)
identify and quantify the expression of neuroregulatory
proteins that might be related with the hMSC secretome-
mediated processes involved in neuroprotection, neural
repair, and neurodifferentiation and (2) evaluate to what
extent the secretome of different hMSC populations (eg,
BMSCs, ASCs, and HUCPVCs) can differ in the above-
referred phenomena.
Materials and Methods
Cell culture
Human bone marrow, umbilical cord perivascular cells, and
adipose tissue-derived stem cells. BMSCs (n = 3, Stem Cell
Technologies) were thawed and expanded according to pro-
tocols previously described in our laboratory [12]. Briefly,
BMSCs were cultured in a-MEM (Invitrogen) supplemented
with 10% of fetal bovine serum (FBS, Biochrom) and 1%
penicillin–streptomycin antibiotic (Invitrogen). After reach-
ing 80%–90% of confluence, cells were enzymatically dis-
sociated with 0.05% trypsin-EDTA (Invitrogen), plated at a
density of 4,000 cells/cm2, and maintained at 37C, 5% hu-
midified CO2, 95% air, and 90% relative humidity. The cul-
ture medium was changed every three days.
HUCPVCs (n = 3) were kindly provided by Professor
J.E.Davies (University of Toronto, Canada; Ethical approval
had been previously obtained from the University of Tor-
onto/Sunnybrook and Women’s College Health Sciences
Centre, Toronto) and ASCs (n = 3) by Professor J.M.Gimble
(Pennington Biomedical Research Center/Tulane Uni-
versity; All protocols were reviewed and approved by the
Pennington Biomedical Research Center Institutional Re-
search Boards before the study, Tulane University). Cell
isolation from umbilical cord and adipose tissue was per-
formed according to the protocols previously described
[13,14]. As for BMSCs, ASCs and HUCPVCs were cultured
in a-MEM (Invitrogen) supplemented with 10% of FBS
(Biochrom) and 1% penicillin–streptomycin antibiotic (In-
vitrogen). After reaching 80%–90% of confluence, cells
were enzymatically dissociated with 0.05% trypsin-EDTA
(Invitrogen), plated at a density of 4,000 cells/cm2, and
maintained at 37C, 5% humidified CO2, 95% air, and 90%
relative humidity. The culture medium was changed every
3 days.
Conditioned medium collection and concentration. The CM
used was collected from BMSC, ASC, and HUCPVC cul-
tures in passage 6 (P6) as follows: cells were plated at a
density of 12,000 cells/cm2 in T175 tissue culture flasks
(Nunc) and allowed to grow for 3 days. After this, the flasks
were first washed five times with phosphate-buffered saline
without Ca2+/Mg2+ (Invitrogen), and then washed twice
with Neurobasal A medium (Invitrogen). Following this,
Neurobasal A medium supplemented with 1% kanamycin
(Invitrogen) was added to the cells. After 24 h, the CM was
collected and concentrated (100·) by centrifugation using
a 5 kDa cutoff concentrator (Vivaspin; GE Healthcare).
All collected CMs were frozen at -80C until it was
required.
Proteomics–mass spectrometry
and SWATH acquisition
Secreted proteins were precipitated from the concentrated
medium using trichloroacetic acid (TCA; Sigma)-Acetone
(Sigma) procedure [15]. Briefly, samples were incubated at -
80C with TCA [final concentration of 20% (v/v)] for 30min
and centrifuged (20,000 · g) for 20min at 4C. Protein pellets
were then solubilized in ice-cold (-20C) acetone, aided by
ultrasonication (VC750; Vibracell-Sonics&Materials), and
centrifuged (20,000· g) for 20min. The obtained pellets
were thereafter resuspended in triethylammonium bicarbon-
ate buffer (TEAB, 1M; Sigma), aided by ultrasonication, and
centrifuged (20,000 · g) for 5min to remove the insoluble
material.
For liquid digestion, samples were reduced by the addition
of 4 mL of tris(2-carboxymethyl)phosphine (TCEP, 50mM;
Sigma) to 45 mL of each sample, followed by an ultra-
sonication step for 2min. Then, 2 mL of the cysteine blocking
agent, methanethiosulfonate (600mM; Sigma), was added
and samples were left to react for 10min at room temperature.
TEAB was added to bring the final volume of each sample to
100 mL, and the samples were digested with trypsin overnight
(2 mg trypsin/sample), at 37C, with swirling at 560 rpm.
Reactions were stopped by the addition of 2 mL of formic acid
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(FA; Amresco) and the peptides were dried by rotary evap-
oration under vacuum. After protein digestion, samples were
desalted using OMIX tips containing C18 stationary phase
(Argilent Technologies). Eluted peptides spiked with iRT
peptides (Biognosys AG) were dried and resuspended in a
mobile phase containing 0.1% FA and 2% of acetonitrile
(ACN) aided by ultrasonication (20% intensity). To remove
insoluble material, samples were centrifuged (14,000· g;
5min) before LC-MS/MS analysis. Initially, peptide samples
were resolved by LC using a C18 AR reverse phase column
(ChromXP, 300mm · 15 cm, 3 mm particle size, 120 A˚ pore
size; Eksigent) at 5 mL/min using a 25-min ACN linear gra-
dient (from 2% to 35%) in 0.1% FA into the mass spec-
trometer (Triple TOF 5600 system; AB SCIEX). For
tandem mass spectrometry (MS/MS) analysis, samples were
analyzed in two phases. First, each sample was analyzed with
a mass spectrometer operating in information-dependent ac-
quisition (IDA) to detect and identify the maximal number of
proteins within sample mixtures. For IDA, the mass spec-
trometer was set to scan full spectra of ions in the 350–
1,250m/z range, during 250ms, followed by 20 ion frag-
mentation spectra (MS/MS) scans (100–1,500m/z range),
with 1MS/MS being acquired for 100ms before adding those
ions to the exclusion list for 20 s. The selection/isolation
criteria for ion fragmentation comprised intensity, where ions
had tomeet a minimum threshold of 70 counts/s with a charge
state between +2 and +5. Ions were fragmented in the colli-
sion cell (rolling collision) using collision energy spread
of 5 eV. The library was obtained by searching against the
human and bovine species from SwissProt database, using
the Protein Pilot software (v4.5; AB SCIEX). Afterward,
samples were analyzed using the SWATH acquisition
method, which allows detection and an accurate quantifica-
tion of the identified proteins. For this purpose, the instrument
was set to isolate ions with a 26m/z width, in a loop mode,
over the precursor mass range of 350–1,100m/z, and 30
overlapping windows were constructed. For instrument cal-
ibration, the survey scan was set to scan full spectra of peptide
ions in the 350–1,250m/z range (50ms) at the beginning of
each cycle. SWATH fragmentation spectra were collected
from 100–1,500m/z using an accumulation time of 100ms
for all fragment ion scans, which resulted in a cycle time of
3.25 s. For optimal fragmentation of precursors within the
isolation windows, a 15 eV spread of collision was applied.
The SWATH quantitative information was extracted from the
SWATH-MS data using the SWATH processing plug-in for
PeakView (2.0.01 version; AB SCIEX). Peak areas were
extracted (in an extracted ion chromatogram window of
1.5min) for up to five target fragment ions (automatically
selected) up to 15 peptides (selected based on aAU6c FDR lower
that 1%) per protein. The levels of the proteins were estimated
by summing all the transitions from all the peptides for a given
protein [16] and were normalized to the total intensity of the
sample. Quantification results are expressed as the average
protein intensity that corresponds to the relative protein in-
tensity in proportion to the internal standard (IS, GFP).
Statistical analysis
Statistical analysis was performed using one-way ANOVA
with Bonferroni post hoc test for multiple group compari-
son, using the program GraphPad Prism five (GraphPad
Software, Inc.). Data are presented as mean – standard de-
viation, and differences were considered significant when
P< 0.05.
Results and Discussion
To evaluate the variation of the hMSC secretome as a
function of tissue source, the secretome of hMSCs derived
from the bone marrow, umbilical cord, and adipose tissue
was characterized through a proteomic approach based on
SWATH-MS acquisition. From this analysis, we observed
that BMSC, HUCPVC, and ASC secretomes disclosed a
different profile ( b F1Fig. 1A). Through the use of Venn dia-
grams, we were able to identify a total of 451 proteins, in
which 134 proteins were common to the three MSC popu-
lations (Fig. 1B). From these, 121 were quantified, respec-
tively. When we analyzed the relative protein levels of the
three (MSC populations) secretomes for specific proteins
with actions into the CNS, we were able to find 20 pro-
teins. Cystatin C (Cys C), albumin serum, IL-6, pigment
epithelium-derived factor (PEDF), plasminogen activator
inhibitor-1 (PAI-1), plasma protease C1 inhibitor (C1-Inh),
decorin (DCN), clusterin (CLUS), cadherin-2 (CADH2),
semaphorin 7A (SEM7A), and glia-derived nexin (GDN)
were found to be implicated in extracellular actions. In fact,
all of them have been characterized by the presence of an N-
terminal signaling peptide, which is essential for proteins to
be secreted through the endoplasmic reticulum–Golgi clas-
sical pathway. In addition, reports have also indicated that
these proteins can also be exocytosed through exosomes
[17] or microvesicles [18]. The remaining proteins, namely
cyclophilin A (CYPA), cyclophilin B (CYPB), DJ-1, thior-
edoxin (TRX), peroxiredoxin-1 (PRDX1), heat shock pro-
tein 27 (HSP27), UCHL1, and brain acid-soluble protein 1
(BASP-1), were found to be involved in intracellular ac-
tions, and as the above-referred ones, they can also be se-
creted by exosomes [19] or microvesicles [20]. Finally,
galectin 1 (Gal-1) was involved in both extracellular and
intracellular actions [21], being also secreted by the same
way as the above-referred proteins. In addition to these
findings, it was also found that some other proteins with
important roles in CNS regulations were only present in the
secretome of each MSC population. For instance, b1-4-
galactosyltransferase (b4Gal-T) was only found in the se-
cretome of ASCs; stromal-derived factor-1a (SDF-1a) and
gelsolin in the secretome of BMSCs; and finally, Cyr61
protein and colony-stimulating factor 1 (CSF-1) in the se-
cretome of HUCPVCs. In the following sections, a discus-
sion based on the function of each of these proteins within
neurodegenerative and injury processes within the CNS will
be made.
Protection against oxidative stress
Regarding oxidative stress, studies indicate that eight of the
proteins found in the secretome of BMSCs, ASCs, and
HUCPVCs, namely DJ-1, TRX, CYPA, CYPB, CYSC,
PRDX1, AS, and HSP27, work as antioxidative mediators
[22–26]. For instance, DJ-1, which is amultifunctional protein
from the peptidase C56 family, may become activated in the
presence of reactive oxygen species (ROS) under conditions
of oxidative stress, acting as a transcriptional regulator of
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antioxidative gene batteries [27]. Similar evidence was found
in in vivo models of PD and focal cerebral ischemia after
intranigral or intrastriatal injection, respectively [28]. Re-
garding TRX, which has been described as a cytoplasmic
redox-active protein, studies have suggested that it may act as
neuroprotective protein in in vitro models of PD and transient
focal ischemia, through its antioxidant function upon over-
expression and/or administration of human recombinant (hr)
TRX [23,29]. CYPA and CYPB are proteins from the im-
munophilin family of peptidyl-prolyl cis-trans isomerases [30]
whose role in CNS remains largely unknown. Nevertheless,
they have already shown to be neuroprotective agents against
amyloid beta (Ab)-induced neurotoxicity, suppressing ROS
formation [22,25]. Cys C, a cysteine protease inhibitor, was
found to be a protector of cortical neurons against hydrogen
peroxidase (H2O2)-induced oxidative stress upon exogenous
administration of hrCys C [31]. Similar findings were also
described forPRDX1, as a cytoplasmic thioredoxin-dependent
peroxidase reductase, in which its overexpression in dopami-
nergic (DA) neuronal cell lines has shown to counteract DA
cell death by acting as an ROS (superoxide anion and H2O2)
scavenger in a 6-OHDA model of PD [32].
Human SA, which is the most abundant protein in plasma,
was found to be a powerful antioxidant mediator, being able
FIG. 1. Graphical representation
of HUCPVC, ASC, and BMSC CM
proteomic analysis by mass spec-
trometry. CM analysis revealed that
the BMSCs, ASCs and HUCPVCs
had different secretome profiles (A).
Through the use of Venn diagrams
(B), it was possible to identify 134
proteins, which were common to all
three cell populations, from which a
total of 121 proteins secreted by
HUCPVCs, ASCs and BMSCs were
quantified. The color scale shown
illustrates the relative expression of
the indicated proteins across the
samples: red denotes low expres-
sion and green denotes high ex-
pression. ASCs, adipose tissue stem
cells; BMSC, bone marrow stem
cell; HUCPVC, human umbilical
cord perivascular cell. Color images
available online at www.liebertpub
.com/scd
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to reduce the neuronal death induced by H2O2 or copper/
ascorbic acid oxidant stimulation [33]. Finally, HSP27 from
the subfamily of small HSPs, which is mostly known by its
role in providing thermotolerance to cells [34] and chaper-
one activity in proteins [35], has demonstrated to be a
modulator of ischemic brain damage in vivo, inhibiting the
levels of oxidative stress [24,26]. In addition to these
functions, we have observed that the relative expression
levels of the above-referred proteins were significantly dif-
ferent in the CM of BMSCs, ASCs, and HUCPVCs (F2c Fig. 2).
Specifically, CYPB was the only protein upregulated in
BMSC CM when compared with HUCPVC (P < 0.05) and
ASC (P < 0.01) CMs. CYPA, on the other hand, was just
significantly more expressed in BMSC CM when compared
with ASC CM (P < 0.05). Additionally, it was also found
that DJ-1 was just upregulated in the BMSC CM when
compared with HUCPVC CM (P< 0.05). On the other hand,
upon comparison of protein profile between HUCPVC and
ASC CMs, results showed that TRX and CYPA expression
was significantly elevated in HUCPVCs, whereas the op-
posite was observed regarding Cys C expression (P < 0.05).
Taken together, results indicate that BMSC secretome might
have a more prone antioxidative profile when compared with
HUCPVCs and ASCs. In fact, we have also identified gel-
solin, which was only present in the BMSC secretome, and
that has been described as a stronger antioxidative molecule
in neurodegenerative disorders such as AD [36], thereby
supporting the prominent antioxidative properties of BMSCs.
Apoptosis
CYPA, CYPB, Cys C, IL-6, Gal-1, and HSP27 have been
described as antiapoptotic proteins [24–26,31,37,38].
CYPA, CYPB, and Cys C have shown to have a dual role in
CNS, playing as antioxidative and antiapoptotic modulators
in in vitro models of AD and PD. For instance, the admin-
istration of hrCYPA or CYPB revealed to prevent PC12 cell
death against Ab-mediated apoptosis when exposed to ab
peptides [22,25]. On the other hand, Cys C was demon-
strated to be a neuroprotective agent against Ab and 6-
OHDA-induced apoptotic neuronal death [31,38,39]. IL-6
has also shown to have a protective role within the CNS. For
instance, intracerebral administration of hrIL-6 was dem-
onstrated to be an antiapoptotic agent, able to reduce neu-
ronal cell death in transient and permanent rodent models
of cerebral ischemia [40]. Concerning Gal-1, described as
an endogenous soluble mammalian lectin, it was already
demonstrated that its infusion into the cerebello-medullar
cistern led to the reduction of neuronal apoptosis in a rat
model of focal cerebral ischemia by inducing the expression
of brain-derived neurotrophic factor [21], also known as an
antiapoptotic factor [41]. Similar outcomes were also de-
scribed for HSP27, respectively [24,26].
Concerning the relative expression levels of the above-
referred proteins in the CM of BMSCs, ASCs and HUCPVCs,
the results revealed that CYPA, CYPB, CYSC, and IL-6 were
differently expressed, while Gal-1 and HSP27 were not
(P> 0.05; b F3Fig. 3). CYPB was found to be significantly upre-
gulated in BMSC CM (P< 0.05; P< 0.01), whereas IL-6 was
highly expressed in HUCPVC CM (P< 0.05). Concerning
differences between HUCPVC and ASC CMs, IL-6 and
CYPA expression was significantly superior in HUCPVC CM
when compared with the ASC CM (P< 0.05), while the op-
posite was observed regarding Cys C expression (P< 0.05).
Therefore, these results indicate that both BMSC and
HUCPVC secretomes may exhibit a similar antiapoptotic
profile, in which the sole expression of SDF-1a and gelsolin by
BMSCs and CSF-1 by HUCPVCs (defined as neuroprotective
and antiapoptotic agents [36,42–44] supported even more the
above-referred outcomes.
Excitotoxicity
Excitotoxicity represents a pathological process by which
neurons are damaged and killed by the overactivation of
excitatory neurotransmitter receptors involved in stroke,
traumatic brain injury, and neurodegenerative diseases [45].
The IL-6, PEDF, and PAI-1 identified in the proteomic
FIG. 2. Specific HUCPVC, ASC, and BMSC CM proteins with potential antioxidative functions onAU4c CNS physiology.
Proteomic analysis revealed that CYPB was significantly more expressed in BMSC CM when compared with HUCPVC and
ASC CMs. CYPA and CYPB expression was significantly elevated in BMSC CM when compared with the ASC CM.
Similarly, comparisons between BMSC CM and HUCPVC CM showed that CYPB and DJ-1 were significantly more
expressed in BMSC CM. On the other hand, statistical differences between HUCPVC CM and ASC CM revealed that
expression of TRX and CYPA was significantly increased in HUCPVC CM, whereas CYSC was significantly upregulated
in ASC CM. Data are expressed as mean –SD. *P< 0.05, **P < 0.01, ***P< 0.001. IS, internal standard; SD, standard
deviation.AU8c
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analysis are described as important neuroprotective media-
tors against glutamate-induced excitotoxicity [46,47]. In
addition to its antiapoptotic action, IL-6 has also the ability
to reduce neuronal damage induced by glutamate in hip-
pocampal neurons in vitro [48] as well as in striatal cho-
linergic neurons in vivo [49]. Similarly, PEDF, which has
been described as a multifunctional protein and a non-
inhibitory member of the serine protease inhibitor (SERPIN)
gene family, was found to be a neuroprotective protein of
cerebellar granule cells and hippocampal neurons against
glutamate cytotoxicity in vitro [46]. In addition, in neuro-
degenerative disorders such as PD, PEDF revealed to be
a neuroprotective agent against 6-OHDA-induced excito-
toxicity [50]. Finally, PAI-1, also a member of the serine
protease inhibitor (Serpin E1) superfamily [51], in the re-
combinant form, has been described as a protective player
against the N-methyl-D-aspartate (NMDA)-induced excito-
toxicity in cortical neurons through modulation of NMDA-
Ca2+ influx upon exogenous stimulation [47]. In terms of the
relative expression levels of the above-referred proteins, the
proteomic results revealed that IL-6 and PEDF were dif-
ferently expressed in HUCPVCs (upregulated, P < 0.05) and
ASCs (upregulated, P < 0.01;F4c Fig. 4), which indicates that
their secretome can play a role in mediating neuroprotection
induced by excitotoxicity phenomena.
As mentioned above, in addition to the ability of proteins
present in hMSC secretome to regulate processes, such as
oxidative stress, apoptosis, and glutamate-mediated ex-
citotoxicity, proteomic analysis also revealed the presence
of proteins involved in the regulation of proteasomal deg-
radation, neurogenesis, inflammation, glial scarring, and
toxic protein deposition (F5c Fig. 5). One of these proteins was
UCHL1, which is both a ubiquitin (UB) hydrolase [52] and
UB-ligase enzyme mostly localized in neurons [53]. UCHL1
has been shown to be involved in regulation of proteasomal
degradation [54], which has been linked with neurodegen-
erative diseases such as AD and PD [53]. As can be ob-
served in Fig. 5, results show that UCHL1 was significantly
upregulated in HUCPVC CM (P < 0.05). For TRX, besides
its antioxidant activity, it was recently reported that TRX is
also a promoter of hippocampal neurogenesis, leading to
cognitive recovery in a cerebral ischemia model [55]. Like
UCHL1, TRX was also significantly increased in HUCPVC
CM (P< 0.05).
Another protein that was found in hMSC secretome was
plasma protease C1-Inh, a glycoprotein that belongs to the
superfamily of serine protease inhibitors (Serpin G1) [56]. At
the same time, it is also an endogenous inhibitor of the
complement classical pathway and the contact-kinin systems
[56]. Actually, the former system is involved in a variety of
immune inflammatory responses, whereas the contact-kinin
system is involved not only in inflammation but also in co-
agulation and blood pressure control, both of which have been
shown to play crucial roles in the pathophysiology of ische-
mic stroke [57]. As displayed in Fig. 5, C1-Inh was upregu-
lated in BMSC CM (P < 0.05). The role of this protein in the
CNS is still largely unknown, but it would be interesting to
evaluate its effects on the modulation of the activity of mi-
croglial cells.
Proteomic analysis also revealed the presence of a small
leucine proteoglycan protein, named DCN [58], which was
FIG. 3. Specific HUCPVC, ASC, and BMSC CM proteins with potential antiapoptotic effects on CNS physiology.
Proteomic analysis revealed that CYPB was significantly upregulated in BMSC CM when compared with HUCPVC CM
and ASC CM. In contrast, IL-6 was highly expressed in HUCPVC CM when compared with BMSC and ASC CM. CYSC
was found upregulated in ASC CM when compared with HUCPVC CM. In opposition, CYPA was downregulated in ASC
CM when compared with both HUCPVC and BMSC CMs. Data are expressed as mean – SD. *P < 0.05, **P < 0.01,
***P< 0.001. IL-6, interleukin-6; IS, internal standard.AU8c
FIG. 4. Specific HUCPVC, ASC, and BMSC CM proteins
with potential antiexcitotoxicity effects on CNS physiology.
Proteomic analysis revealed that IL-6 was significantly more
expressed in HUCPVC CM when compared with ASC and
BMSC CMs. Results also showed that PEDF expression was
significantly elevated in ASC CM when compared with
HUCPVC and BMSC CMs. Data are expressed as mean –
SD. *P < 0.05, **P < 0.01, ***P< 0.001. IS, internal stan-
dard; PEDF, Pigment epithelium-derived factor. bAU8
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the only antiscarring quantifiable molecule found in the
analysis of hMSC CM. Indeed, hrDCN administration has
been reported to promote axon regeneration, even across the
lesions, by acting as an antiscarring agent both in vitro and
in vivo [58]. Actually, DCN antiscarring effect was attrib-
uted to the reduction of inflammatory fibrosis, astrogliosis,
and levels of several scar-related elements (eg, chondroitin
sulfate proteoglycans). The expression of this protein was
increased in the ASC secretome (P < 0.001) and also in
BMSCs relative to HUCPVCs (P< 0.01).
Finally, regarding proteins involved in neuroprotection
phenomena, within the hMSC secretome, we have also
found CLUS, which is an extracellular chaperone found in
all human fluids [59]. In fact, it has been shown that CLUS
displays a protective function against Ab-induced neuro-
toxicity in vitro [59]. However, although the exact mecha-
nism by which secreted CLUS protects neuronal cells from
Ab neurotoxicity is unclear, it is thought to be related with
CLUS-Ab complex formation, leading to the attenuation of
Ab aggregation and subsequent degradation by lysosomes
[59]. In terms of expression, results showed that although a
much more noticeable expression of CLUS was found in
ASC CM, no significant differences were found when
compared with the other hMSC populations. Collectively,
results indicate that HUCPVC CM seems to have a more
pronounced role in mediating neuroprotective activity
FIG. 5. Specific HUCPVC, ASC, and BMSC CM proteins with potential actions in the regulation of proteasome deg-
radation (UCHL1), neurogenesis (TRX, Gal-1), inflammation (c1-Inh), glial scarring (DCN), and toxic protein deposition
(CLUS). Proteomic analysis revealed that UCHL1 expression was significantly higher in HUCPVC CM when compared
with both ASC and BMSC CMs. TRX expression was also significantly elevated in HUCPVC CM when compared with
ASC CM. C1-inh was significantly increased in BMSC CM when compared with HUCPVC CM. On the other hand, results
showed that DCN expression was significantly upregulated in ASC CM when compared with both HUCPVC and BMSC
CMs and also in BMSC CM when compared with ASC CM. Data are expressed as mean – SD. *P < 0.05, **P < 0.01,
***P < 0.001. IS, internal standard; UCHL1, ubiquitin-carboxy-terminal hydrolase 1.
FIG. 6. Specific HUCPVC, ASC, and BMSC CM proteins with potential effects in neurite outgrowth and neuronal
differentiation. From the comparative analysis of the secreted proteins in the different MSC CM populations, we have
identified proteins involved in neurodifferentiation, namely PEDF, CADH2, and IL-6. IL-6 and PEDF were significantly
upregulated in HUCPVC CM and ASC CM, respectively, when compared with the other CM groups. CADH2 were
significantly increased in HUCPVC CM when compared with ASC CM. In contrast, PEDF was found to be significantly
downregulated in HUCPVC CM and BMSC CM when compared with ASC CM. On the other hand, LC-MS/MS analysis
also revealed that proteins involved in neurite outgrowth (SEM7A, GDN, and BASP-1) and GDN expression were sig-
nificantly elevated in BMSC CM when compared with both HUCPVC and ASC CMs. HUCPVC CM exhibited significantly
lower expression of SEM7A and GDN when compared with both ASC and BMSC CMs. Data are expressed as mean – SD.
*P < 0.05, **P < 0.01, ***P< 0.001. GDN, glia-derived nexin; IS, internal standard.AU8c
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associated with abnormal proteasomal degradation, and also
in promoting neurogenesis.
Neurite outgrowth and neurodifferentiation
Although the mechanisms by which hMSC secretome is
able to modulate the behavior of neural progenitors remain
unclear from the molecular point of view, studies have de-
termined that a network of multiple signaling pathways
and transcriptional regulators controls the differentiation of
neural progenitors [60]. In fact, from our proteomic analysis,
we have found that PEDF, CADH2, and IL-6 have been
related to processes such as neurite outgrowth and neuron
differentiation (F6c Fig. 6) [61–63]. Besides its role as a neu-
roprotective factor, PEDF has been described as a mediator
of neuronal survival and differentiation. Exogenous addition
of PEDF to human Y-79 retinoblastoma cells and embryonic
chick spinal cord motor neurons not only promotes survival
but also stimulates the formation of a dense meshwork of
neurites [62,64]. Similarly, IL-6 has also been demonstrated
to induce neuronal differentiation in PC12 cells [61]. On the
other hand, CADH2, a neuronal cell adhesion glycoprotein,
has been found to induce both morphological and bio-
chemical features of differentiated neurons in embryonic
carcinoma P19 cells [63]. Regarding relative expression
levels, IL-6 and CADH2 were significantly increased in
HUCPVC CM when compared with ASC CM (P < 0.05),
whereas the contrary was observed concerning PEDF
(P < 0.01). Nevertheless, these data indicate the presence of
proteins that promote neurodifferentiation in the secretome
of the three hMSC populations, further reinforcing the
neurodifferentiation properties of the secretome of these
cells. In addition to these findings, we have also found
proteins documented to play roles in axon guidance and
neurite outgrowth, namely SEM7A [65], GDN [66], and
BASP-1 [67] (Fig. 6). SEM7A, which belongs to the se-
maphorin family of axon guidance proteins, has been de-
scribed to enhance axon growth from olfactory bulb
explants in both its soluble and membrane-bound forms
[65]. GDN, a serine protease inhibitor from the serpin
family [66], has also been shown to promote neurite out-
growth in neuroblastoma (NB2a) cells, and also in rat hip-
pocampal cells [68]. Finally, BASP-1, a major protein of
neuronal lipid rafts, when overexpressed in PC12E2 cells (a
subclone of PC12 cells) and rat primary hippocampal neu-
rons, was found to be a stronger stimulator of neurite out-
growth in both cell types [67]. Thus, as can be observed in
Fig. 6, HUCPVC CM expression of GDN and SEM7A was
significantly downregulated when compared with both
BMSC CM (P < 0.01) and ASC CM (P< 0.05). Thus, from
the obtained data, BMSC and ASC CMs might exhibit a
similar profile in promoting neurite outgrowth when com-
pared with HUCPVCs. In fact, in addition to the above-
quantified proteins, we have also identified b4Gal-T (only in
the de ASC CM) and SDF-1a (only in BMSC CM), which
have been described as promoters and regulators of neurite
outgrowth in the CNS [69–72]. At the same time, despite the
(apparently) less prominent profile of HUCPVCs on this
topic, we have also identified important molecules (only in
their CM) playing a role in the regulation of neural pro-
genitor cell maintenance and maturation as Cyr61 and CSF-
1, respectively [73,74].
Conclusions
In the present work, we have characterized and contrasted
the secretome of BMSCs, ASCs, and HUCPVCs through
proteomic-based analysis, identifying and quantifying the
relative expression differences among these hMSC popula-
tions. Based on the relative protein expression levels in the
hMSC CM, our results showed that hMSCs derived from
different tissues may have distinct profiles, which could lead
to a different action(s) against distinct physiological or
pathogenic processes involved in CNS disorders/injuries.
Indeed, the evaluation of the hMSC CM secretion profile,
based on the differential expression of proteins with neu-
roprotection character, indicated that BMSC CM might be
the most advantageous choice for a therapy designed to
reduce oxidative stress, while HUCPVCs and ASCs could
more beneficial in the protection against excitotoxicity. On
the other hand, results also suggest that HUCPVC CM may
be less appropriate for antiscarring phenomena, whereas it
might be the most indicated for targeting abnormal protea-
somal degradation. Likewise, both BMSC and HUCPVC
CMs might be advantageous as antiapoptotic agents.
Therefore, future studies should focus on validating the ef-
ficiency of the CM of each individual hMSC source for each
of the aforementioned biological processes.
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EntryjEntry name Protein name_UNIPROT recommended
P23284jPPIB_HUMAN Peptidyl-prolyl cis-trans isomerase B (PPIase B)/Cyclophilin B (CYPB)
P30086jPEBP1_HUMAN Phosphatidylethanolamine-binding protein 1
P14618jKPYM_HUMAN Pyruvate kinase PKM
P31949jS10AB_HUMAN Protein S100-A11
P60174jTPIS_HUMAN Triosephosphate isomerase
Q15149jPLEC_HUMAN Plectin
P13693jTCTP_HUMAN Translationally controlled tumor protein
P22392jNDKB_HUMAN Nucleoside diphosphate kinase B
Q15293jRCN1_HUMAN Reticulocalbin-1
Q9BRK5jCAB45_HUMAN 45 kDa Calcium-binding protein
P07737jPROF1_HUMAN Profilin-1
P09211jGSTP1_HUMAN Glutathione S-transferase P
Q16610jECM1_HUMAN Extracellular matrix protein 1
P07437jTBB5_HUMAN Tubulin beta chain
O75368jSH3L1_HUMAN SH3 domain-binding glutamic acid-rich-like protein
P02751jFINC_HUMAN Fibronectin
P09486jSPRC_HUMAN SPARC
P61769jB2MG_HUMAN Beta-2-microglobulin
Q09666jAHNK_HUMAN Neuroblast differentiation-associated protein AHNAK
P01034jCYTC_HUMAN Cystatin-C (CYTC)
P12109jCO6A1_HUMAN Collagen alpha-1(VI) chain
Q01995jTAGL_HUMAN Transgelin
P62158jCALM_HUMAN Calmodulin
P60709jACTB_HUMAN Actin, cytoplasmic 1
P13611jCSPG2_HUMAN Versican core protein
P08670jVIME_HUMAN Vimentin
P06733jENOA_HUMAN Alpha-enolase
O43707jACTN4_HUMAN Alpha-actinin-4
P08123jCO1A2_HUMAN Collagen alpha-2(I) chain
O43852jCALU_HUMAN Calumenin
Q14847jLASP1_HUMAN LIM and SH3 domain protein 1
P09651jROA1_HUMAN Heterogeneous nuclear ribonucleoprotein A1
P23528jCOF1_HUMAN Cofilin-1
P22626jROA2_HUMAN Heterogeneous nuclear ribonucleoproteins A2/B1
P37802jTAGL2_HUMAN Transgelin-2
P05121jPAI1_HUMAN Plasminogen activator inhibitor 1 (PAI-1)
O94985jCSTN1_HUMAN Calsyntenin-1
P06703jS10A6_HUMAN Protein S100-A6
Q15942jZYX_HUMAN Zyxin
P19022jCADH2_HUMAN Cadherin-2 (CADH2)
P20908jCO5A1_HUMAN Collagen alpha-1(V) chain
Q9UBP4jDKK3_HUMAN Dickkopf-related protein 3
P51884jLUM_HUMAN Lumican
P08476jINHBA_HUMAN Inhibin beta A chain
P16949jSTMN1_HUMAN Stathmin
P21333jFLNA_HUMAN Filamin-A
P63104j1433Z_HUMAN 14-3-3 Protein zeta/delta
P02462jCO4A1_HUMAN Collagen alpha-1(IV) chain
P04792jHSPB1_HUMAN Heat shock protein beta-1/Heat shock 27 kDa protein (HSP27)
Q15121jPEA15_HUMAN Astrocytic phosphoprotein PEA-15
P04075jALDOA_HUMAN Fructose-bisphosphate aldolase A
P60660jMYL6_HUMAN Myosin light polypeptide 6
P02545jLMNA_HUMAN Prelamin-A/C
P67936jTPM4_HUMAN Tropomyosin alpha-4 chain
P10599jTHIO_HUMAN Thioredoxin (TRX/TRX1)
P99999jCYC_HUMAN Cytochrome c
P11142jHSP7C_HUMAN Heat shock cognate 71 kDa protein (HSC 70)
Q06830jPRDX1_HUMAN Peroxiredoxin-1 (PRDX1)
(continued)
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Supplementary Table S1. (Continued)
EntryjEntry name Protein name_UNIPROT recommended
P05787jK2C8_HUMAN Keratin, type II cytoskeletal 8
P05231jIL6_HUMAN Interleukin-6 (IL-6)
P61604jCH10_HUMAN 10 kDa Heat shock protein, mitochondrial
P09936jUCHL1_HUMAN Ubiquitin carboxyl-terminal hydrolase isozyme L1 (UCH-L1)
P38159jRBMX_HUMAN RNA-binding motif protein, X chromosome
O75347jTBCA_HUMAN Tubulin-specific chaperone A
P05783jK1C18_HUMAN Keratin, type I cytoskeletal 18
P62937jPPIA_HUMAN Peptidyl-prolyl cis-trans isomerase A (PPIase A)/Cyclophilin A (CYPA)
Q8N6G6jATL1_HUMAN ADAMTS-like protein 1
Q9HCU0jCD248_HUMAN Endosialin
O00391jQSOX1_HUMAN Sulfhydryl oxidase 1
P12107jCOBA1_HUMAN Collagen alpha-1(XI) chain
P36955jPEDF_HUMAN Pigment epithelium-derived factor (PEDF)
P09871jC1S_HUMAN Complement C1s subcomponent
Q6EMK4jVASN_HUMAN Vasorin
P10909jCLUS_HUMAN Clusterin (CLUS)
Q08380jLG3BP_HUMAN Galectin-3-binding protein
Q99715jCOCA1_HUMAN Collagen alpha-1(XII) chain
P02452jCO1A1_HUMAN Collagen alpha-1(I) chain
Q12841jFSTL1_HUMAN Follistatin-related protein 1
P28300jLYOX_HUMAN Protein-lysine 6-oxidase
P12110jCO6A2_HUMAN Collagen alpha-2(VI) chain
P26447jS10A4_HUMAN Protein S100-A4
P35555jFBN1_HUMAN Fibrillin-1
P21810jPGS1_HUMAN Biglycan
P16035jTIMP2_HUMAN Metalloproteinase inhibitor 2
P98160jPGBM_HUMAN Basement membrane-specific heparan sulfate proteoglycan core protein
P26022jPTX3_HUMAN Pentraxin-related protein PTX3
P05997jCO5A2_HUMAN Pentraxin-related protein PTX3
P07585jPGS2_HUMAN Decorin (DCN)
Q96D15jRCN3_HUMAN Reticulocalbin-3
Q05682jCALD1_HUMAN Reticulocalbin-3
P36222jCH3L1_HUMAN Chitinase-3-like protein 1
Q16270jIBP7_HUMAN Insulin-like growth factor-binding protein 7
P02461jCO3A1_HUMAN Collagen alpha-1(III) chain
P01033jTIMP1_HUMAN Metalloproteinase inhibitor 1
Q9H299jSH3L3_HUMAN SH3 domain-binding glutamic acid-rich-like protein 3
P30101jPDIA3_HUMAN Protein disulfide-isomerase A3
P07858jCATB_HUMAN Cathepsin B
P02768jALBU_HUMAN Serum albumin (SA)
P22692jIBP4_HUMAN Insulin-like growth factor-binding protein 4
05155jIC1_HUMAN Plasma protease C1 inhibitor (C1 Inh)
P07996jTSP1_HUMAN Thrombospondin-1
Q15063jPOSTN_HUMAN Periostin
P07093jGDN_HUMAN Glia-derived nexin (GDN)
P09382jLEG1_HUMAN Galectin-1 (Gal-1)
P29966jMARCS_HUMAN Myristoylated alanine-rich C-kinase substrate
P04080jCYTB_HUMAN Cystatin-B
Q14767jLTBP2_HUMAN Latent-transforming growth factor beta-binding protein 2
P08572jCO4A2_HUMAN Collagen alpha-2(IV) chain
Q99497jPARK7_HUMAN DJ-1
O14498jISLR_HUMAN Immunoglobulin superfamily containing leucine-rich repeat protein
P24592jIBP6_HUMAN Insulin-like growth factor-binding protein 6
Q08629jTICN1_HUMAN Testican-1
Q15582jBGH3_HUMAN Transforming growth factor-beta-induced protein ig-h3
Q76M96jCCD80_HUMAN Coiled-coil domain-containing protein 80
O75326jSEM7A_HUMAN Semaphorin-7A (SEM7A)
Q8NBS9jTXND5_HUMAN Thioredoxin domain-containing protein 5
P08253jMMP2_HUMAN 72 kDa type IV collagenase
P23142jFBLN1_HUMAN Fibulin-1
P50454jSERPH_HUMAN Serpin H1
Q02818jNUCB1_HUMAN Nucleobindin-1
P80723jBASP1_HUMAN Brain acid-soluble protein 1 (BASP-1)
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